{
    "clinical_study": {
        "@rank": "18197", 
        "arm_group": [
            {
                "arm_group_label": "Low Dose MK-8226", 
                "arm_group_type": "Experimental", 
                "description": "MK-8226 administered intravenously (IV) at a weight-based dose every 2 weeks for a period of 12 weeks."
            }, 
            {
                "arm_group_label": "Mid-Low Dose MK-8226", 
                "arm_group_type": "Experimental", 
                "description": "MK-8226 administered IV at a weight-based dose every 2 weeks for a period of 12 weeks."
            }, 
            {
                "arm_group_label": "Mid-High Dose MK-8226", 
                "arm_group_type": "Experimental", 
                "description": "MK-8226 administered IV at a weight-based dose every 2 weeks for a period of 12 weeks."
            }, 
            {
                "arm_group_label": "High Dose MK-8226", 
                "arm_group_type": "Experimental", 
                "description": "MK-8226 administered IV at a weight-based dose every 2 weeks for a period of 12 weeks."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo administered IV every 2 weeks for a period of 12 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a 3-part study to assess the safety, tolerability, efficacy, pharmacokinetics,\n      pharmacodynamics, and immunogenicity of MK-8226 in participants with moderate to severe\n      atopic dermatitis.  Part 1 will be done to find the maximum tolerated dose (MTD) of MK-8226\n      and to assess safety and pharmacokinetics.  Part 2 will evaluate safety, pharmacokinetics,\n      and preliminary efficacy.  Part 3, if done, will further define safety and pharmacokinetics,\n      and will explore MK-8226 pharmacokinetic/pharmacodynamics to model the optimal dose range\n      for future studies if Part 1 does not supply sufficient information to do this."
        }, 
        "brief_title": "A Study of Intravenous MK-8226 in Participants With Moderate-to-Severe Atopic Dermatitis (MK-8226-003 AM2)", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Atopic Dermatitis", 
        "condition_browse": {
            "mesh_term": [
                "Dermatitis", 
                "Dermatitis, Atopic"
            ]
        }, 
        "detailed_description": {
            "textblock": "Part 1 of the study is a multiple rising dose assessment of the safety, tolerability, and\n      pharmacokinetics of MK-8226 for a period of 12 weeks followed by a 20-week off-treatment\n      follow-up period.\n\n      Part 2 of the study is an assessment of the safety, tolerability, and efficacy of MK-8226\n      for 12 weeks followed by a 20-week off-treatment follow-up period.\n\n      An interim futility analysis will be performed when approximately 40% of the participants\n      that have been treated with study drug have completed the active treatment portion of the\n      study (Week 12) while additional patients will continue to be enrolled into Part 2 of the\n      study. If the interim results support study continuation, additional participants may be\n      enrolled in Part 3 of the study.\n\n      In Part 3 of the study, participants will be treated with MK-8226 for a period of 12 weeks\n      followed by a 20-week off-treatment follow-up period to evaluate pharmacokinetic and\n      pharmacokinetic correlations to assist with modeling the dose range planned for further\n      studies."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Body weight >=40 kg\n\n          -  Clinical diagnosis of atopic dermatitis for at least 6 months prior\n\n          -  Candidate for systemic or phototherapy (i.e., failed topical treatment)\n\n          -  Moderate-to-severe disease as defined by Body Surface Area (BSA) \u226510%, EASI \u226512, and\n             IGA \u22653\n\n          -  No clinically significant abnormality on electrocardiogram\n\n          -  No history of active or latent TB and no signs or symptoms suggestive of TB\n\n          -  No history of active or latent TB and no signs or symptoms suggestive of TB\n\n          -  History of inadequate response to a stable (\u2265 1 month) regimen of topical\n             corticosteroids or calcineurin inhibitors within 3 months before the screening visit\n\n        Exclusion Criteria:\n\n          -  Concurrent significant skin disease\n\n          -  Any significant organ dysfunction within 6 months prior\n\n          -  History of clinically significant heart disease\n\n          -  History of neoplastic disease\n\n          -  Positive for hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)\n\n          -  Infection requiring oral antibiotics within 2 weeks prior\n\n          -  Receipt of a live virus vaccine within 4 weeks prior\n\n          -  Inability to refrain from topical or systemic therapy during course of the study\n\n          -  Had major surgery or donated or lost >=1 unit of blood within 4 weeks prior\n\n          -  Participation in another study within 4 weeks prior\n\n          -  Current or regular user of illicit drugs or a history of drug or alcohol abuse within\n             1 year prior\n\n          -  Pregnant, breast-feeding, or anticipated to conceive during the course of the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "170", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 19, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01732510", 
            "org_study_id": "8226-003"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Low Dose MK-8226", 
                    "Mid-Low Dose MK-8226", 
                    "Mid-High Dose MK-8226", 
                    "High Dose MK-8226"
                ], 
                "description": "MK-8226 administered IV at a weight-based dose every 2 weeks for 12 weeks.", 
                "intervention_name": "MK-8226", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo administered intravenously every 2 weeks for a period of 12 weeks.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 15, 2014", 
        "number_of_arms": "5", 
        "official_title": "A Phase Ib Randomized, Double-Blinded, Placebo-Controlled Multiple Rising Dose Clinical Trial to Evaluate the Safety, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Intravenous MK-8226 in Patients With Moderate to Severe Atopic Dermatitis", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Number of Participants Experiencing at Least One Adverse Event (AE)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 32 Weeks"
            }, 
            {
                "measure": "Number of Participants Discontinuing Study Treatment Due to AEs", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 12 Weeks"
            }, 
            {
                "measure": "Mean Change From Baseline in the Eczema Area and Severity Index (EASI) for Study Part 2", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 12"
            }
        ], 
        "removed_countries": {
            "country": [
                "United States", 
                "Austria", 
                "Canada", 
                "Denmark", 
                "Finland", 
                "Germany"
            ]
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01732510"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Mean Change From Baseline in Chemokine (C-C motif) Ligand 17 (CCL17) in Study Part 2", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 12"
            }, 
            {
                "measure": "Mean Area Under the Curve From Time Zero to Tau (AUC0-tau) of MK-8226 Following Multiple Intravenous Dose Administration", 
                "safety_issue": "No", 
                "time_frame": "Predose on Day 1 Through Postdose on Day 224"
            }, 
            {
                "measure": "Mean AUC From Time Zero to Last Measurement (AUC0-last) of MK-8226 Following Multiple Intravenous Dose Administration", 
                "safety_issue": "No", 
                "time_frame": "Predose on Day 1 Through Postdose on Day 224"
            }, 
            {
                "measure": "Mean Time to Maximum Serum Concentration (Cmax) of MK-8226 Following Multiple Dose Intravenous Administration", 
                "safety_issue": "No", 
                "time_frame": "Predose on Day 1 Through Postdose on Day 224"
            }, 
            {
                "measure": "Mean Clearance (CL) of MK-8226 Following Multiple Dose Intravenous Administration", 
                "safety_issue": "No", 
                "time_frame": "Predose on Day 1 Through Postdose on Day 224"
            }, 
            {
                "measure": "Mean Volume of Distribution (Vd) of MK-8226 Following Multiple Intravenous Administration", 
                "safety_issue": "No", 
                "time_frame": "Predose on Day 1 Through Postdose on Day 224"
            }, 
            {
                "measure": "Mean Terminal Half Life (T1/2) of MK-8226 Following Multiple Dose Intravenous Administration", 
                "safety_issue": "No", 
                "time_frame": "Predose on Day 1 Through Postdose on Day 224"
            }, 
            {
                "measure": "Mean Change From Baseline in the Eczema Area and Severity Index (EASI) for Study Part 2", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 4, Week 8, Week 24"
            }, 
            {
                "measure": "Proportion of Participants With a Investigator Global Assessment (IGA) Score of Clear or Almost Clear in Study Part 2", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 4, Week 8, Week 12, Week 24"
            }, 
            {
                "measure": "Mean Plasma Chemokine (C-C motif) Ligand 22 (CCL22) Level in Study Part 2", 
                "safety_issue": "No", 
                "time_frame": "48 Hours, Week 4, Week 12, Week 16"
            }, 
            {
                "measure": "Mean Change From Baseline in the Scoring Atopic Dermatitis Scale  (SCORAD) in Study Part 2", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 4, Week 12, Week 24"
            }, 
            {
                "measure": "Mean Change From Baseline in Participant Pruritis in Study Part 2", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 4, Week 12, Week 24"
            }, 
            {
                "measure": "Mean Change From Baseline in Participant Sleep Disturbance in Study Part 2", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 4, Week 12, Week 24"
            }, 
            {
                "measure": "Number of Participants Requiring As-Needed Oral Antihistamines as Rescue Medication in Study Part 2", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 12"
            }, 
            {
                "measure": "Mean Change from Baseline in the Participant's Global Impression of Disease Status in Study Part 2", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 4, Week 12, Week 24"
            }, 
            {
                "measure": "Proportion of Participants With >=50% Improvement in EASI Score", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 12, Week 24"
            }, 
            {
                "measure": "Number of Participants Positive for Anti-Drug Antibody Formation", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 32"
            }
        ], 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}